Drugs that inhibit mTOR, such as rapamycin, are Food and Drug Administration (FDA) approved for organ transplant rejection prevention, treatment of certain tumors,80 pulmonary lymphangioleiomyomatosis,81 and are applied in drug-eluding stents to prevent restenosis of coronary arteries.82 This evidence concerns the gene MTOR and lung lymphangioleiomyomatosis.